跳至主要内容
临床试验/NCT05828238
NCT05828238招募中早期 1 期

PET Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

Affiliated Hospital of Jiangnan University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2023年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
招募中
发起方
入组人数
10
试验地点
1
主要终点
Evaluation of tissue distribution of [18F]-DEVD-2

研究概览

简要总结

This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients voluntarily signed informed consent;
  • Age18-70, male or female;
  • Diagnosed with stage 2 or 3 breast cancer
  • Solid tumors、masses larger than 2cm with lymph node metastasis
  • Pathology is HER3+、triple negative patients
  • Patients to be treated with neoadjuvant chemotherapy

排除标准

  • Age greater than or equal to 70 years old
  • Abnormal liver and kidney function (more than five times the normal value)
  • Diagnosis level of breast cancer stage 4 or second time tumor patients

研究组 & 干预措施

[18F]SF-DEVD-2

Experimental

干预措施: [18F]SF-DEVD-2 (Drug)

[18F]SF-DEVD-2

Experimental

干预措施: [18F]-FDG (Drug)

结局指标

主要结局

Evaluation of tissue distribution of [18F]-DEVD-2

时间窗: 7 days

Biodistribution of \[18F\] -DEVD-2 evaluated by the maximum standardized uptake value(SUVmax) in various organs during repeated \[18F\]-DEVD scans will be reported.

次要结局

未报告次要终点

研究者

发起方
Affiliated Hospital of Jiangnan University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chunjing Yu

Director

Affiliated Hospital of Jiangnan University

研究点 (1)

Loading locations...

相似试验